Friedreich’s Ataxia (FA) is a rare, genetic, neurodenegerative, mulit-system, life-altering disorder. Onset of symptoms is usually between the ages of 5 and 15. Earlier the onset typically means a more aggressive disease path.
- muscle weakness and loss of coordination in the arms and legs requiring wheelchair usage
- vision & hearing impairment
- slurred speech
- aggressive scoliosis that often requires spinal fusion
- life-threatening heart disease called hypertrophic cardiomyopathy
The Friedreich’s Ataxia Research Alliance (FARA) was established in 1998 by a group of patient families and leading FA scientists. FARA is supporting research that will improve the quality and length of life for those diagnosed with Friedreich’s Ataxia and will lead to treatments that eliminate its symptoms. Thanks to generous donors and the tireless efforts of Friedreich’s Ataxia families, FARA has raised and devoted more than $16 million to supporting FA research around the world since its establishment. It is estimated that we need to raise $4 million this year to fund these clinical trials. Please see www.curefa.org for more information on FARA.